UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) 8 Clarke Drive, Suite 3 Cranbury, NJ 08512 (Ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regula ...

PART I. FINANCIAL INFORMATION [Condensed Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(Unaudited)) The company reported an increased net loss of $18.4 million for Q1 2022, with total assets decreasing to $315.0 million due to reduced cash and cash equivalents, resulting in a net cash use of $18.0 million from operations [Condensed Balance Sheets (Unaudited)](index=5&type=section&id=Condensed%20Balance%20Sheets%20(Unaudited)) As of March 31, 2022, total assets decreased to $315.0 million, primarily due to reduced cash, while liabilities remained stable and stockholders' equity declined to $291.8 million due to the net loss for the period Condensed Balance Sheet Data (in thousands) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $115,772 | $172,467 | | Marketable securities, current | $167,221 | $124,696 | | Total current assets | $288,040 | $301,286 | | Total assets | $315,008 | $331,568 | | **Liabilities & Equity** | | | | Total current liabilities | $11,685 | $12,219 | | Total liabilities | $23,165 | $23,009 | | Accumulated deficit | $(186,159) | $(167,726) | | Total stockholders' equity | $291,843 | $308,559 | [Condensed Statements of Operations and Comprehensive Loss (Unaudited)](index=6&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss%20(Unaudited)) For Q1 2022, the company reported an increased net loss of $18.4 million, or ($0.41) per share, primarily driven by higher operating expenses, including increased Research and Development and General and Administrative costs Condensed Statement of Operations (in thousands, except per share data) | Metric | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Research and development | $11,836 | $7,500 | | General and administrative | $6,783 | $4,174 | | Total operating expenses | $18,619 | $11,674 | | Loss from operations | $(18,619) | $(11,674) | | Net loss | $(18,433) | $(11,602) | | Net loss per share | $(0.41) | $(0.26) | [Condensed Statements of Cash Flows (Unaudited)](index=8&type=section&id=Condensed%20Statements%20of%20Cash%20Flows%20(Unaudited)) Net cash used in operating activities increased to $18.0 million for the first quarter of 2022, with significant cash used in investing activities for marketable securities, resulting in a net decrease of $56.7 million in cash and cash equivalents during the quarter Condensed Statement of Cash Flows (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(17,998) | $(12,904) | | Net cash used in investing activities | $(38,825) | $(139,897) | | Net cash provided by financing activities | $128 | $162 | | **Net decrease in cash and cash equivalents** | **$(56,695)** | **$(152,639)** | [Notes to Unaudited Condensed Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) The notes confirm the company's precision oncology focus, state that current liquidity is sufficient for the next twelve months despite losses, and detail significant operating lease commitments and available shares under the equity incentive plan - The company is a precision oncology firm focused on developing small molecule therapies targeting p53, having devoted its efforts to R&D and raising capital since its 2013 inception[25](index=25&type=chunk) - As of March 31, 2022, the company had cash, cash equivalents, and marketable securities totaling **$294.8 million**. Management believes these funds are adequate to support operations for at least the next twelve months[27](index=27&type=chunk) - The company signed a lease for a new headquarters in Princeton, NJ, extending through 2032. As of March 31, 2022, total future minimum lease payments under all operating leases are **$16.7 million**[56](index=56&type=chunk)[58](index=58&type=chunk) - As of March 31, 2022, there were **5,321,975 shares** available for issuance under the 2020 Equity Incentive Plan[63](index=63&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's p53-targeting cancer therapies, anticipates continued significant operating expenses and net losses, and highlights strong liquidity of $294.8 million expected to fund operations through 2023 - The company is a precision oncology firm developing therapies targeting p53 mutations. Its lead product candidate, PC14586, is in a Phase 1/2 clinical trial, with the first patient dosed in Q4 2020[79](index=79&type=chunk)[80](index=80&type=chunk) - The company expects operating expenses to increase significantly as it advances product candidates through clinical development and seeks regulatory approval[80](index=80&type=chunk) - As of March 31, 2022, the company had **$294.8 million** in cash, cash equivalents, and marketable securities, which is expected to be sufficient to fund operations at least through 2023[96](index=96&type=chunk)[100](index=100&type=chunk) [Results of Operations](index=19&type=section&id=Results%20of%20Operations) Operating loss for Q1 2022 increased to $18.6 million, primarily driven by a $4.3 million rise in R&D expenses for the PC14586 clinical trial and a $2.6 million increase in G&A expenses due to expanded headcount and infrastructure Comparison of Operating Expenses (in thousands) | Expense Category | Q1 2022 | Q1 2021 | Change | | :--- | :--- | :--- | :--- | | Research and development | $11,836 | $7,500 | $4,336 | | General and administrative | $6,783 | $4,174 | $2,609 | | **Total operating expenses** | **$18,619** | **$11,674** | **$6,945** | - The **$4.3 million** increase in R&D expenses was primarily due to a **$3.7 million** increase in development costs for the PC14586 Phase 1/2 clinical trial and a **$0.7 million** increase in personnel-related costs[92](index=92&type=chunk) - The **$2.6 million** increase in G&A expenses was mainly due to a **$1.5 million** increase in personnel and office costs from higher headcount and a **$0.6 million** increase in facility costs for the new Princeton office[93](index=93&type=chunk)[97](index=97&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, primarily from $294.8 million in cash and marketable securities from its 2020 IPO, is expected to fund operations through 2023, with future funding likely required for development and commercialization Financial Position Summary (in thousands) | Category | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $115,772 | $172,467 | | Total financial assets | $294,766 | $314,074 | | Total working capital | $276,355 | $289,067 | - The company's cash runway is expected to last at least through 2023, based on current research and development plans[100](index=100&type=chunk) - The company has a shelf registration statement on Form S-3 for a potential future offering of up to **$150.0 million**, though no shares have been sold under it as of the reporting date[96](index=96&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=22&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) The company's critical accounting policies include Research and Development Costs, requiring estimates for accrued expenses, and Stock-Based Compensation, which uses the Black-Scholes model with significant assumptions for fair value determination - A key estimate is for accrued research and development expenses, which involves reviewing contracts and communicating with vendors (CROs, CMOs) to determine costs for services performed but not yet invoiced[116](index=116&type=chunk) - The fair value of stock options is estimated using the Black-Scholes model, which requires management to make significant assumptions, including using historical volatilities of comparable public companies due to its own limited trading history[117](index=117&type=chunk)[118](index=118&type=chunk)[119](index=119&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is from interest rates on its $294.8 million in short-term financial assets, which is not considered material, and it currently has no significant foreign currency exchange rate risk - The company's market risk is primarily from interest rate changes affecting its **$294.8 million** in cash, cash equivalents, and marketable securities, but this exposure is not considered material[122](index=122&type=chunk)[123](index=123&type=chunk) - There is no significant current exposure to foreign currency exchange rate risk, though this could become a factor with future international vendor contracts[124](index=124&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2022, with no material changes to internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of March 31, 2022[126](index=126&type=chunk) - No changes in internal control over financial reporting occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, these controls[127](index=127&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings that are expected to have a material adverse effect on its business - The company reports no current involvement in litigation or legal proceedings that would likely have a material adverse effect[130](index=130&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported, except for new disclosures concerning international operations, including differing regulatory requirements, sociopolitical instability, foreign currency fluctuations, and supply chain disruptions - No material changes to risk factors are reported, except for new disclosures regarding risks associated with international operations[131](index=131&type=chunk) - Newly highlighted international risks include: differing foreign regulatory requirements, sociopolitical instability, foreign currency fluctuations, and supply chain disruptions due to geopolitical conflicts or trade restrictions[134](index=134&type=chunk)[142](index=142&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities and no material change in the planned use of approximately $223.2 million in net proceeds from its September 2020 IPO - There were no unregistered sales of equity securities in the period[136](index=136&type=chunk) - The company received net proceeds of approximately **$223.2 million** from its IPO in September 2020, and there has been no material change in the planned use of these funds[137](index=137&type=chunk)[138](index=138&type=chunk) [Defaults Upon Senior Securities](index=26&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) None - The company reports no defaults upon senior securities[140](index=140&type=chunk) [Mine Safety Disclosures](index=26&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - This item is not applicable to the company[141](index=141&type=chunk) [Other Information](index=26&type=section&id=Item%205.%20Other%20Information) Not applicable - This item is not applicable to the company[142](index=142&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the company's certificate of incorporation, bylaws, various agreements, and certifications by the principal executive and financial officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) 8 Clarke Drive, Suite 3 Cranbury, NJ 08512 (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other ju ...

PART I. FINANCIAL INFORMATION [Item 1. Condensed Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20%28Unaudited%29) This section presents unaudited condensed financial statements, including balance sheets, statements of operations, equity, and cash flows, with detailed notes on financial position and accounting policies [Condensed Balance Sheets (Unaudited)](index=5&type=section&id=Condensed%20Balance%20Sheets%20%28Unaudited%29) Condensed balance sheets show decreased total assets and equity, primarily from reduced cash, offset by increased marketable securities | Metric | June 30, 2021 (Unaudited) (in thousands) | December 31, 2020 (in thousands) | Change (k) | % Change | | :-------------------------------- | :------------------------------------- | :------------------------------- | :--------- | :------- | | Cash and cash equivalents | $189,423 | $361,422 | $(171,999) | -47.6% | | Marketable securities, current | $128,926 | $— | $128,926 | N/A | | Marketable securities, noncurrent | $20,613 | $— | $20,613 | N/A | | Total current assets | $323,080 | $364,761 | $(41,681) | -11.4% | | Total assets | $355,910 | $365,531 | $(9,621) | -2.6% | | Total current liabilities | $7,504 | $6,410 | $1,094 | 17.1% | | Total liabilities | $18,063 | $6,410 | $11,653 | 181.8% | | Total stockholders' equity | $337,847 | $359,121 | $(21,274) | -5.9% | [Condensed Statements of Operations and Comprehensive Loss (Unaudited)](index=6&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss%20%28Unaudited%29) Statements of operations show increased net loss for Q2 and H1 2021, driven by higher R&D and G&A expenses | Metric (in thousands) | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Change | % Change | | :-------------------- | :------------------------------- | :------------------------------- | :----- | :------- | | Research and development | $7,664 | $5,804 | $1,860 | 32.0% | | General and administrative | $5,386 | $2,281 | $3,105 | 136.1% | | Total operating expenses | $13,050 | $8,085 | $4,965 | 61.4% | | Net loss | $(12,874) | $(7,967) | $(4,907) | 61.6% | | Metric (in thousands) | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | Change | % Change | | :-------------------- | :----------------------------- | :----------------------------- | :----- | :------- | | Research and development | $15,163 | $11,760 | $3,403 | 28.9% | | General and administrative | $9,560 | $3,979 | $5,581 | 140.2% | | Total operating expenses | $24,723 | $15,739 | $8,984 | 57.1% | | Net loss | $(24,476) | $(15,221) | $(9,255) | 60.8% | [Condensed Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Unaudited)](index=7&type=section&id=Condensed%20Statements%20of%20Convertible%20Preferred%20Stock%20and%20Stockholders%27%20%28Deficit%29%20Equity%20%28Unaudited%29) Equity statement details changes from preferred stock conversion, net losses, and increased paid-in capital from stock compensation | Metric (in thousands) | June 30, 2021 | December 31, 2020 | | :-------------------- | :------------ | :---------------- | | Additional paid-in capital | $472,196 | $469,001 | | Accumulated deficit | $(134,356) | $(109,880) | | Total stockholders' equity | $337,847 | $359,121 | | Metric (in thousands) | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :-------------------- | :----------------------------- | :----------------------------- | | Stock-based compensation expense | $1,777 | $679 | [Condensed Statements of Cash Flows (Unaudited)](index=8&type=section&id=Condensed%20Statements%20of%20Cash%20Flows%20%28Unaudited%29) Cash flow statements show a net decrease in cash for H1 2021, primarily from cash used in investing activities | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(22,145) | $(15,034) | | Net cash (used in) provided by investing activities | $(150,450) | $19,931 | | Net cash (used in) provided by financing activities | $1,418 | $(124) | | Net (decrease) increase in cash, cash equivalents, and restricted cash | $(171,177) | $4,773 | | Cash, cash equivalents, and restricted cash - end of period | $190,245 | $78,051 | [Notes to Unaudited Condensed Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) Notes provide essential context and detailed disclosures for financial statements, covering accounting policies, fair value, and commitments - PMV Pharmaceuticals, Inc. is a clinical-stage oncology company focused on p53 mutations, incorporated in Delaware in March 2013. The company completed an IPO on September 25, 2020, raising **$223.2 million** net proceeds[26](index=26&type=chunk)[28](index=28&type=chunk) - The company has incurred significant net losses and negative cash flows from operations since inception, with an accumulated deficit of **$134.4 million** as of June 30, 2021. Management believes current cash and equivalents are sufficient for at least the next twelve months[29](index=29&type=chunk) - No material changes to significant accounting policies since December 31, 2020, except for the adoption of ASU No. 2016-02 (Leases) and ASU 2019-12 (Income Taxes) effective January 1, 2021. The lease standard adoption resulted in recording ROU assets of **$970k** and lease liabilities of **$1,129k**[30](index=30&type=chunk)[45](index=45&type=chunk)[47](index=47&type=chunk) Fair Value of Financial Assets (in thousands) as of June 30, 2021 | Financial Assets | Carrying Amount | Fair Value | Level 1 | Level 2 | Level 3 | | :-------------------- | :-------------- | :--------- | :------ | :-------- | :------ | | Money market funds | $38,865 | $38,865 | $38,865 | $— | $— | | Corporate securities | $263,799 | $263,799 | $— | $263,799 | $— | | Government securities | $32,740 | $32,740 | $— | $32,740 | $— | | **Total** | **$335,404** | **$335,404** | **$38,865** | **$296,539** | **$—** | - The company signed a new lease in January 2021 for **50,581 square feet** of office and laboratory space in Princeton, NJ. The lease term extends through 2032, with total payments of **$19.6 million**. Lease liabilities as of June 30, 2021, were **$11,235k**[65](index=65&type=chunk)[66](index=66&type=chunk) Stock-Based Compensation Expense (in thousands) | Period | 2021 | 2020 | | :---------------------- | :---- | :--- | | Three Months Ended June 30 | $1,150 | $383 | | Six Months Ended June 30 | $1,777 | $679 | - Total compensation cost related to nonvested awards not yet recognized is **$17,526k**, expected to be recognized over a weighted-average period of **3.4 years**[78](index=78&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and results, covering business overview, financial components, comparative performance, and liquidity [Overview](index=18&type=section&id=Overview) PMV Pharmaceuticals is a clinical-stage oncology company developing p53 mutation therapies, with significant losses and a lead candidate in Phase 1/2 clinical trial - PMV Pharmaceuticals is a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies designed to target p53 mutations[92](index=92&type=chunk) - The company initiated a **Phase 1/2 clinical trial** in October 2020 for its lead product candidate, PC14586, which was granted FDA Fast Track Designation for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation[93](index=93&type=chunk) Financial Performance (in millions) | Metric | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2021 | Accumulated Deficit (June 30, 2021) | | :---------------- | :------------------------------- | :----------------------------- | :---------------------------------- | | Net Loss | $(12.9) | $(24.5) | N/A | | Accumulated Deficit | N/A | N/A | $(134.4) | [Components of Results of Operations](index=19&type=section&id=Components%20of%20Results%20of%20Operations) This section outlines key financial components: revenue (none), operating expenses (R&D, G&A), and interest income, detailing their nature and future trends - The company has not generated any revenue from product sales to date and does not expect to in the foreseeable future[97](index=97&type=chunk) - Research and development expenses, primarily consisting of personnel costs, third-party contractor services, and manufacturing, are expensed as incurred and are expected to increase substantially as product candidates advance through clinical trials[98](index=98&type=chunk)[100](index=100&type=chunk) - General and administrative expenses, including personnel costs and professional services, are also expected to increase due to operating as a public company and advancing product candidates[101](index=101&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) This section compares financial performance for Q2 and H1 2021 vs 2020, highlighting increased operating expenses and net losses Net Loss (in thousands) | Period | 2021 | 2020 | Change | % Change | | :---------------------- | :-------- | :-------- | :-------- | :------- | | Three Months Ended June 30 | $(12,874) | $(7,967) | $(4,907) | 61.6% | | Six Months Ended June 30 | $(24,476) | $(15,221) | $(9,255) | 60.8% | Total Operating Expenses (in thousands) | Period | 2021 | 2020 | Change | % Change | | :---------------------- | :------ | :------ | :------ | :------- | | Three Months Ended June 30 | $13,050 | $8,085 | $4,965 | 61.4% | | Six Months Ended June 30 | $24,723 | $15,739 | $8,984 | 57.1% | [Comparison of the Three Months ended June 30, 2021 and 2020](index=20&type=section&id=Comparison%20of%20the%20Three%20Months%20ended%20June%2030%2C%202021%20and%202020) Q2 2021 saw R&D expenses increase by $1.9 million, G&A expenses rise by $3.1 million, and net interest income decrease Research and Development Expenses (in thousands) | Category | 2021 | 2020 | Change | % Change | | :------------------------ | :---- | :---- | :----- | :------- | | Research | $2,180 | $1,560 | $620 | 39.7% | | Development | $3,484 | $2,204 | $1,280 | 58.1% | | Personnel related | $1,718 | $1,862 | $(144) | -7.7% | | Stock-based compensation | $282 | $178 | $104 | 58.4% | | **Total R&D Expenses** | **$7,664** | **$5,804** | **$1,860** | **32.0%** | - General and administrative expenses increased by **$3.1 million** to **$5.4 million** in 2021, primarily due to increased headcount for infrastructure, finance and legal support, directors and officers insurance, and facility-related costs for the new Princeton, NJ office building[107](index=107&type=chunk)[109](index=109&type=chunk) Interest Income, Net (in thousands) | Period | 2021 | 2020 | Change | % Change | | :---------------------- | :--- | :--- | :----- | :------- | | Three Months Ended June 30 | $113 | $157 | $(44) | -28.0% | [Comparison of the Six Months ended June 30, 2021 and 2020](index=21&type=section&id=Comparison%20of%20the%20Six%20Months%20ended%20June%2030%2C%202021%20and%202020) H1 2021 saw R&D expenses increase by $3.4 million, G&A expenses surge by $5.6 million, and net interest income decrease Research and Development Expenses (in thousands) | Category | 2021 | 2020 | Change | % Change | | :------------------------ | :---- | :---- | :----- | :------- | | Research | $4,631 | $3,207 | $1,424 | 44.4% | | Development | $6,374 | $4,593 | $1,781 | 38.8% | | Personnel related | $3,625 | $3,640 | $(15) | -0.4% | | Stock-based compensation | $533 | $320 | $213 | 66.6% | | **Total R&D Expenses** | **$15,163** | **$11,760** | **$3,403** | **28.9%** | - General and administrative expenses increased by **$5.6 million** to **$9.6 million** in 2021, primarily due to a **$2.9 million** increase in personnel and office-related expenses (headcount), a **$1.0 million** increase in finance and legal support, a **$1.2 million** increase for directors and officers insurance, and a **$0.5 million** increase due to facility-related costs for the new Princeton, NJ office building[110](index=110&type=chunk) Interest Income, Net (in thousands) | Period | 2021 | 2020 | Change | % Change | | :---------------------- | :--- | :--- | :----- | :------- | | Six Months Ended June 30 | $241 | $563 | $(322) | -57.2% | [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) The company relies on equity financing, has significant losses, and holds $190.2 million in cash and $149.5 million in marketable securities, projected to fund operations through 2023, but future funding is anticipated - Since inception, the company has not generated revenue and has incurred significant operating losses and negative cash flows. Operations have been financed primarily through issuances of convertible preferred and common stock, including **$223.2 million** net proceeds from an IPO in September 2020[113](index=113&type=chunk) Liquidity Position (in millions) as of June 30, 2021 | Asset Category | Amount | | :---------------------------------- | :------- | | Cash, cash equivalents, and restricted cash | $190.2 | | Short-term marketable securities | $128.9 | | Long-term marketable securities | $20.6 | | Accumulated deficit | $(134.4) | - Based on current research and development plans, the company expects its cash, cash equivalents, and marketable securities as of June 30, 2021, to be sufficient to fund operations at least through **2023**[115](index=115&type=chunk) - Future funding requirements are substantial and unpredictable due to preclinical and clinical development activities. The company expects to fund future needs through equity/debt financing or collaboration arrangements, which may result in dilution or restrictive covenants[114](index=114&type=chunk)[116](index=116&type=chunk) Cash Flows (in thousands) for Six Months Ended June 30 | Activity | 2021 | 2020 | | :-------------------------------- | :---------- | :---------- | | Cash used in operating activities | $(22,145) | $(15,034) | | Cash (used in) provided by investing activities | $(150,450) | $19,931 | | Cash (used in) provided by financing activities | $1,418 | $(124) | | Net increase in cash, cash equivalents, and restricted cash | $(171,177) | $4,773 | [Off-Balance Sheet Arrangements](index=24&type=section&id=Off-Balance%20Sheet%20Arrangements) The company has not entered into any off-balance sheet arrangements during the periods presented - The company does not currently have, nor in the past had, any off-balance sheet arrangements[124](index=124&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=24&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) Financial statements require significant estimates and judgments, especially for R&D costs, with no material changes to critical accounting policies reported - The company's critical accounting policies involve a high degree of judgment and complexity, particularly regarding research and development costs, accrued R&D costs, and related prepaid expenses[127](index=127&type=chunk)[128](index=128&type=chunk) - No material changes to critical accounting policies were made during the six months ended June 30, 2021, other than those described in Note 2 of the financial statements[127](index=127&type=chunk) [Recent Accounting Pronouncements](index=24&type=section&id=Recent%20Accounting%20Pronouncements) Refer to Note 2 of the unaudited condensed financial statements for recent accounting pronouncements - For a description of recent accounting pronouncements, refer to Note 2 of the notes to the unaudited condensed financial statements[130](index=130&type=chunk) [JOBS Act Accounting Election](index=25&type=section&id=JOBS%20Act%20Accounting%20Election) PMV Pharmaceuticals, an EGC, expects to lose its status by December 31, 2021, becoming a large accelerated filer with increased costs - The company is an 'emerging growth company' (EGC) and has elected to use the extended transition period for complying with new or revised financial accounting standards[132](index=132&type=chunk)[133](index=133&type=chunk) - Based on its common share market value at June 30, 2021, the company expects to lose its EGC status on **December 31, 2021**, and qualify as a large accelerated filer[132](index=132&type=chunk)[164](index=164&type=chunk) - Losing EGC status will result in increased disclosure and governance requirements and associated costs, including higher legal, accounting, and investor relations fees[164](index=164&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Primary market risk is interest rate fluctuations, deemed immaterial due to short-term money market funds and marketable securities, with no significant foreign currency risk - The company's primary market risk relates to interest rate risks, but this exposure is not material due to the nature and amount of its money market funds and short-term marketable securities[134](index=134&type=chunk)[135](index=135&type=chunk) - The company is not currently exposed to significant market risk related to changes in foreign currency exchange rates[136](index=136&type=chunk) [Item 4. Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were effective as of June 30, 2021, with no material changes in internal control over financial reporting - The company's disclosure controls and procedures were **effective** at the reasonable assurance level as of June 30, 2021[138](index=138&type=chunk) - There have been no material changes in the company's internal control over financial reporting during the most recent fiscal quarter[139](index=139&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any litigation or legal proceedings expected to have a material adverse effect - The company is not currently involved in any litigation or legal proceedings that are likely to have any material adverse effect[142](index=142&type=chunk) [Item 1A. Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) This section updates risk factors related to regulatory processes, healthcare legislative measures, and compliance, highlighting potential impacts from government disruptions and cost containment - Changes in funding or disruptions at government agencies like the FDA and SEC could hinder their ability to review and approve new products, potentially delaying development or commercialization[145](index=145&type=chunk)[147](index=147&type=chunk) - Healthcare legislative measures, such as the Affordable Care Act (ACA) and other cost-containment initiatives, could prevent or delay marketing approval, restrict post-approval activities, and affect the company's ability to profitably sell products[148](index=148&type=chunk)[150](index=150&type=chunk)[152](index=152&type=chunk) - The company's business operations and relationships are subject to various healthcare regulatory laws (e.g., federal Anti-Kickback Statute, False Claims Act, HIPAA), and non-compliance could lead to significant penalties, including civil, criminal, and administrative sanctions[158](index=158&type=chunk)[159](index=159&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=31&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This item is not applicable for the current reporting period - Not applicable[166](index=166&type=chunk) [Item 3. Defaults Upon Senior Securities](index=31&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported for this period - None[167](index=167&type=chunk) [Item 4. Mine Safety Disclosures](index=31&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable for the current reporting period - Not applicable[168](index=168&type=chunk) [Item 5. Other Information](index=31&type=section&id=Item%205.%20Other%20Information) This item is not applicable for the current reporting period - Not applicable[169](index=169&type=chunk) [Item 6. Exhibits](index=32&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed as part of this Quarterly Report on Form 10-Q, including organizational documents, equity plans, agreements, and certifications - Exhibits include the Amended and Restated Certificate of Incorporation, Restated Bylaws, and Amended and Restated Investors' Rights Agreement[170](index=170&type=chunk) - Key compensatory plans listed are the 2013 Equity Incentive Plan, 2020 Equity Incentive Plan, and 2020 Employee Stock Purchase Plan, along with various employment and consulting agreements[170](index=170&type=chunk) - Lease agreements for facilities in Cranbury, NJ, and Princeton, NJ, are included. The report also contains certifications of the Principal Executive Officer and Principal Financial Officer[171](index=171&type=chunk)[173](index=173&type=chunk) Signatures [Signatures](index=34&type=section&id=Signatures) The report is signed by David H. Mack, Ph.D., President, CEO, and Director, and Winston Kung, COO and CFO, dated August 13, 2021 - The report was signed by David H. Mack, Ph.D., President, Chief Executive Officer, and Director, and Winston Kung, Chief Operating Officer and Chief Financial Officer[177](index=177&type=chunk) - The signing date for the report was **August 13, 2021**[177](index=177&type=chunk)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdicti ...

Financial Performance - The net loss for the three months ended September 30, 2020, was $8.8 million, an increase of $2.6 million compared to a net loss of $6.2 million for the same period in 2019[100]. - For the nine months ended September 30, 2020, total operating expenses were $24.4 million, an increase of $5.2 million from $19.3 million in the same period of 2019[105]. - The accumulated deficit as of September 30, 2020, was $99.4 million, with continuous losses since the company's inception in March 2013[87]. - Net cash used in operating activities for the nine months ended September 30, 2020, was $22.4 million, compared to $16.9 million for the same period in 2019[118]. - The company expects to incur substantial additional losses in the future as it expands its research and development activities[112]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2020, were $6.0 million, up from $4.9 million in the same period of 2019, reflecting a $1.1 million increase[101]. - Research and development expenses for the nine months ended September 30, 2020, totaled $17.8 million, compared to $15.1 million for the same period in 2019, reflecting a $2.7 million increase[107]. - The company plans to increase research and development expenses for the foreseeable future, although it cannot reasonably estimate the costs or timelines for product development and commercialization[111]. General and Administrative Expenses - General and administrative expenses increased to $2.7 million for the three months ended September 30, 2020, compared to $1.5 million for the same period in 2019, marking a $1.2 million rise[104]. - General and administrative expenses increased to $6.7 million for the nine months ended September 30, 2020, up from $4.2 million in the same period of 2019, reflecting a $2.5 million rise primarily due to personnel-related costs and stock-based compensation[108]. Income and Cash Flow - Interest income, net for the three months ended September 30, 2020, was $40,000, down from $272,000 in the same period of 2019, a decrease of $232,000[104]. - Interest income, net decreased to $0.6 million for the nine months ended September 30, 2020, down from $1.0 million in the same period of 2019, driven by reduced income from cash investments[108]. - Cash and cash equivalents as of September 30, 2020, were $373.1 million, with an accumulated deficit of $99.4 million[110]. - The company raised $243.5 million in gross proceeds from its IPO in September 2020, with net proceeds of $223.2 million after deducting underwriting discounts and commissions[110]. - Investing activities provided $28.0 million of cash during the nine months ended September 30, 2020, primarily from maturities of marketable securities[120]. - Financing activities generated $294.3 million in cash during the nine months ended September 30, 2020, mainly from the IPO and Series D Preferred Stock issuance[122]. Future Outlook - The company does not currently have any product candidates in clinical trials or approved for sale, and it expects to incur significant losses for the foreseeable future[88]. - The company anticipates that operating expenses will increase significantly as it advances product candidates through development and seeks regulatory approval[87]. - The company has not generated any revenue from product sales and does not expect to do so for several years[110].